Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2018 Earnings Presentation
14 slides from Vita Life Sciences's earnings presentation, Aug 24, 2018
Slide 1: Half Year Financial Results for the 6 Months to 30 June 2018
HALF YEAR FINANCIAL RESULTS FOR THE 6 MONTHS TO 30 JUNE 2018 24 August 2018
Slide 2: Business Overview
BUSINESS OVERVIEW • Australian and Asia Pacific based pharmaceutical and healthcare over-the-counter vitamins and supplements business: formulation, packaging, distribution and sale of 3 major consumer retail brands • Over 800 registered vitamins and supplement products (SKU’s) sold in 7 countries:
Slide 3: Half Year 2018 Underlying Results
HALF YEAR 2018 UNDERLYING RESULTS Half year ended June 2018 2017 % Change $’m $’m Revenue 20.1 17.7 Up 13.7% EBITDA 3.1 2.5 Up 20.9% EBIT 2.9 2.4 Up 21.2% Profit before tax 2.9 2.4 Up 21.2% Profit after tax 2.1 1.5 Up 38.4% EPS (Diluted-cents) 3.86 2.75 Up 40.4% Dividend (cents / share) 1.50 1.50 0.
Slide 4: Growth Agenda Taking Shape
GROWTH AGENDA TAKING SHAPE • The Company executed a growth agenda within its core markets in late 2017 • The initial impact delivered solid sales growth from the Australian, Malaysian and Singaporean markets • Group revenue and underlying EBIT increased by 13.7% and 21.2% respectively • The 2nd half
Slide 5: Australia and Malaysia
AUSTRALIA MALAYSIA • Sales within Australia to health food stores remained • Additional promotional activities were undertaken in strong aided by the export of Herbs of Gold products to accordance with the plan in the 1st half, stimulating China sales for both VitaHealth and Herbs of Gold products •
Slide 6: Singapore and Other Asia
SINGAPORE OTHER ASIA • Marginal revenue gains of 3% despite aggressive • Vietnam: continued to grow steadily exceeding growth competition expectations. Increased investment will be implemented in late 2018/ early 2019 to drive market • Underlying EBIT was in line with expectations potential • Contin
Slide 7: Interim Dividend & Cashflows
INTERIM DIVIDEND & CASHFLOWS • Fully franked interim dividend declared of 1.5 cents per share for HY18 (1.5 cents HY17) • Increased gross operating cashflow conversion to EBITDA primarily resulted from higher sales and working capital flows Gross operating cashflow to EBITDA Interim dividend per sha
Slide 8: Shareholder Update
SHAREHOLDER UPDATE Trading update Taking into consideration the Groups growth agenda, including forecasted increases in expenditure within the Australian market in the 2nd half, Directors provide the following guidance for the year ended December 2018: • Revenue - $41m-$42m • EBIT - $4.5m to $5.0m 8
Slide 9: Appendix
APPENDIX 9
Slide 10: Half Year Reported 2018 Results
HALF YEAR REPORTED 2018 RESULTS Half year ended June 2018 2017* $’m $’m Revenue 20.1 17.7 EBITDA^ 3.0 2.1 EBIT^ 2.8 1.9 Profit before tax^ 2.8 1.9 Profit after tax^ 2.0 1.1 EPS (Diluted-cents)^ 3.76 1.94 Dividend (cents / share) 1.50 1.50 *restated ^ include non-recurring share options expense of $6
Slide 11: Balance Sheet
BALANCE SHEET Balance Sheet as at June 2018 December 2017 $m $m Current assets 23.5 22.3 Non-current assets 11.4 10.6 Total assets 34.9 32.9 Current liabilities 6.8 6.1 Non-current liabilities 3.1 2.1 Total Liabilities 9.9 8.2 Net Assets 25.0 24.7 11
Slide 12: Cash Flow
CASH FLOW Cash Flow for the half year ended June 2018 2017 $m $m Receipts from customers 21.5 19.8 Payments to suppliers and employees (18.5) (18.1) Gross operating cash flow 3.0 1.8 EBITDA 3.0 2.1 Gross operating cash flow / EBITDA 100.0% 85.7% Net interest (paid) (0.1) (0.1) Income tax paid (1.0)
Slide 13: Contact
CONTACT Contact: Mr Chin L Khoo, CFO: 0450 734 526 Mr Andrew O’Keefe, Managing Director: 0448 882 556 Office Telephone : +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232 13
Slide 14: Disclaimer
DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a